US4925673A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Delivery systems for pharmacological agents encapsulated with proteinoids
Assignee: CLINICAL TECHNOLOGIES ASSOCIATES Inc 67 SOUTH BEDFORD ROAD MT KISCO NEW YORK 10549 A CORP OF NY
•
Filing: 1987-08-14
•
Granted: 1990-05-15
•
Expires: 2007-08-14
Abstract
Abstract PCT No. PCT/US87/02025 Sec. 371 Date Sep. 8, 1987 Sec. 102(e) Date Sep. 8, 1987 PCT Filed Aug. 14, 1987 PCT Pub. No. WO88/01213 PCT Pub. Date Feb. 25, 1988.Methods are described for targeting the release of an active pharmacological agent in an animal by administering that agent encapsulated in proteinoid microspheres which are stable to the environment encountered from the point of introduction until they migrate to the targeted body organs, fluids or cells and are there unstable. Orally administered delivery systems for insulin, heparin and physostigmine utilize encapsulating microspheres which are predominantly of less than about 10 microns in diameter and pass readily through the gastrointestinal mucosa and which are made of an acidic proteinoid that is stable and unaffected by stomach enzymes and acid, but which releases the microencapsulated agent in pharmacologically active form in the near neutral blood stream. Basic proteinoid microspheres encapsulating a dopamine redox carrier system are administered in the weakly basic, where they are stable, and then enter the blood stream, where the encapsulated agent is similarly released.
Inventors
- 👤 Solomon Steiner
- 👤 Robert Rosen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 22:26
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K47/00; A61K47/50; A61K47/51; A61K47/54; A61K47/559
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
29 words
Composition comprising a pharmacologically active agent encapsulated within protenoid microspheres having diameters predominantly less than about 10 microns and formed from linear thermal condensation polymers of mixed amino acids.
Claim 2
Dependent Claim
29 words
Composition comprising a pharmacologically active agent encapsulated within protenoid microspheres having diameters predominantly less than about 10 microns and formed from linear thermal condensation polymers of mixed amino acids.
Claim 3
Dependent Claim
55 words
Composition of claim 1 wherein said microspheres are stable in at least a segment of the gastrointestinal tract, are unstable in the blood stream and are predominatly less than about 10 microns in diameter so as to readily penetrate the gastrointestinal mucosa and release said active agent in the blood stream in physiologically active form.
Claim 4
Dependent Claim
21 words
Composition of claim 2 wherein said polymer is acidic and said microspheres are stable to acids and enzymes in the mouth.
Claim 5
Dependent Claim
21 words
Composition of claim 2 wherein said polymer is basic and said microspheres are stable in the weakly basic lower digestive tract.
Claim 6
Dependent Claim
14 words
Composition of claim 4 wherein said pharmacological agent is a dopamine redox carrier system.
Claim 7
Dependent Claim
21 words
Composition of claim 2 wherein said polymer is acidic and said microspheres are stable to acids and enzymes in the stomach.
Claim 8
Dependent Claim
10 words
Composition of claim 6 wherein said pharmacological agent is insulin.
Claim 9
Dependent Claim
10 words
Composition of claim 6 wherein said pharmacological agent is heparin.
Claim 10
Dependent Claim
10 words
Composition of claim 6 wherein said pharmacological agent is physostigmine.
Claim 11
Dependent Claim
24 words
Composition of claim 1 wherein said polymer is neutral and said microspheres are stable in the blood stream and are unstable at reduced pH.
Claim 12
Dependent Claim
18 words
Composition of claim 1 wherein said microspheres are predominantly from about 0.5 to about 5.0 microns in diameter.
Claim 13
Dependent Claim
82 words
Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of linear thermal condensation polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominately less than about 10 microns containing the active agent.
Claim 14
Dependent Claim
82 words
Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of linear thermal condensation polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominately less than about 10 microns containing the active agent.
Claim 15
Dependent Claim
11 words
Method of claim 12 wherein said pharmaceutically acceptable liquid is water.
Claim 16
Dependent Claim
36 words
Method of claim 12 including preliminary purification of said polymers by mixing the polymers with water having a pH within said selected range and separating the resulting aqueous solution of said polymers from any insoluble material.
Claim 17
Dependent Claim
53 words
Method for producing an orally administerable composition for delivering insulin to the blood stream in physiologically active form comprising mixing insulin with water and contacting said mixture with a thermal condensation polymer derived from about two parts glutamic acid, about two parts aspartic acid and about one part of neutral or basic alpha-aminoacid.
Claim 18
Dependent Claim
53 words
Method for producing an orally administerable composition for delivering insulin to the blood stream in physiologically active form comprising mixing insulin with water and contacting said mixture with a thermal condensation polymer derived from about two parts glutamic acid, about two parts aspartic acid and about one part of neutral or basic alpha-aminoacid.
Claim 19
Dependent Claim
75 words
Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from linear thermal condensation polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone.
Claim 20
Dependent Claim
75 words
Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from linear thermal condensation polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone.
Claim 21
Dependent Claim
18 words
Method of claim 16 wherein said microspheres are predominantly from about 0.5 to about 5.0 microns in diameter.
Claim 22
Dependent Claim
41 words
Method of claim 16 wherein said microspheres are enterically administered for targeted release in the blood stream and said microspheres are stable in that segment of the gastrointestinal tract into which they are introduced and are unstable in the blood stream.
Claim 23
Dependent Claim
46 words
Method of claim 18 wherein said encapsulated active agent is sublingually introduced into the bloodstream and said microspheres are sufficiently acidic to be stable at a pH of from about 4 to about 6.8 and unstable at a pH of from about 7.35 to about 7.45.
Claim 24
Dependent Claim
48 words
Method of claim 18 wherein said encapsulated active agent is introduced into the bloodstream from the weakly basic lower gastrointestinal tract and said microspheres are sufficiently basic to be stable at a pH of about 8 and unstable at a pH of from about 7.35 to about 7.45.
Claim 25
Dependent Claim
46 words
Method of claim 18 wherein said encapsulated active agent is gastrically introduced into the bloodstream and said microspheres are sufficiently acidic to be stable at a pH of from about 2 to about 6 and unstable at a pH of from about 7.35 to about 7.45.
Claim 26
Dependent Claim
28 words
Method of claim 16 wherein said microspheres are intravenously administered and are stable at a pH of from about 7.35 to about 7.45 and unstable at reduced pH.
Claim 27
Dependent Claim
71 words
Method of treating a diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic protenoid microspheres formed from linear thermal condensation polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45.
Claim 28
Dependent Claim
71 words
Method of treating a diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic protenoid microspheres formed from linear thermal condensation polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-05-14 | 1993-11-13 | 1994-05-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-05-14 | 1997-11-13 | 1998-05-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-05-14 | 2001-11-13 | 2002-05-15 | $7700.00 | Window Closed / Lapsed |